Over diagnosis of bradykinin angioedema in patients treated with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers.
Angioedema
Angiotensin converting enzyme inhibitors
Bradykinin
Mast-cell
Urticaria
Journal
The World Allergy Organization journal
ISSN: 1939-4551
Titre abrégé: World Allergy Organ J
Pays: United States
ID NLM: 101481283
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
24
04
2023
revised:
31
07
2023
accepted:
31
07
2023
medline:
28
8
2023
pubmed:
28
8
2023
entrez:
28
8
2023
Statut:
epublish
Résumé
Bradykinin angioedemas are a potentially serious side effect of angiotensin-converting enzyme inhibitors (ACEI) and more controversially of angiotensin II receptor blockers (ARB). Their challenging diagnosis is based on the absence of any recurrence after more than 6 months of drug discontinuation; otherwise mast-cell driven angioedemas as a differential diagnosis must be considered. The aim of this study was to determine the prevalence of recurrent angioedema in patients referred for ACEI/ARB-induced bradykinin angioedema, after more than 6 months of drug discontinuation. We included ACEI/ARB-treated patients referred for angioedema(s) without hives and unresponsive to antihistamines, after they discontinued ACEI/ARB for at least 6 months. Any C1-inhibitor deficiency was excluded. The primary endpoint was the prevalence of patients with recurrent angioedema after more than 6 months of drug discontinuation and/or developing hives during follow-up. The secondary endpoint was the identification of epidemiological factors associated with any final diagnosis. Thirty-eight of 93 patients (41%) with a suspicion of ACEI/ARB-induced bradykinin angioedema still had recurrent angioedema (n = 27) or developed hives (n = 2) or both (n = 9) after 6 months of drug discontinuation. Good response to icatibant and facial but not oral localization were predictive for the final diagnosis of ACEI/ARB-induced bradykinin angioedema and mast-cell driven angioedema, respectively. In patients referred for acquired angioedema without wheals occurring during ACEI/ARB therapy, 59% finally had a diagnosis of ACEI/ARB-induced bradykinin angioedema whereas 41% were rather diagnosed with mast-cell driven angioedema. The overdiagnosis of ACEI/ARB-induced bradykinin angioedema may deteriorate the management of severe cardiovascular conditions.
Sections du résumé
Background
UNASSIGNED
Bradykinin angioedemas are a potentially serious side effect of angiotensin-converting enzyme inhibitors (ACEI) and more controversially of angiotensin II receptor blockers (ARB). Their challenging diagnosis is based on the absence of any recurrence after more than 6 months of drug discontinuation; otherwise mast-cell driven angioedemas as a differential diagnosis must be considered.
Objective
UNASSIGNED
The aim of this study was to determine the prevalence of recurrent angioedema in patients referred for ACEI/ARB-induced bradykinin angioedema, after more than 6 months of drug discontinuation.
Methods
UNASSIGNED
We included ACEI/ARB-treated patients referred for angioedema(s) without hives and unresponsive to antihistamines, after they discontinued ACEI/ARB for at least 6 months. Any C1-inhibitor deficiency was excluded. The primary endpoint was the prevalence of patients with recurrent angioedema after more than 6 months of drug discontinuation and/or developing hives during follow-up. The secondary endpoint was the identification of epidemiological factors associated with any final diagnosis.
Results
UNASSIGNED
Thirty-eight of 93 patients (41%) with a suspicion of ACEI/ARB-induced bradykinin angioedema still had recurrent angioedema (n = 27) or developed hives (n = 2) or both (n = 9) after 6 months of drug discontinuation. Good response to icatibant and facial but not oral localization were predictive for the final diagnosis of ACEI/ARB-induced bradykinin angioedema and mast-cell driven angioedema, respectively.
Conclusion
UNASSIGNED
In patients referred for acquired angioedema without wheals occurring during ACEI/ARB therapy, 59% finally had a diagnosis of ACEI/ARB-induced bradykinin angioedema whereas 41% were rather diagnosed with mast-cell driven angioedema. The overdiagnosis of ACEI/ARB-induced bradykinin angioedema may deteriorate the management of severe cardiovascular conditions.
Identifiants
pubmed: 37638360
doi: 10.1016/j.waojou.2023.100809
pii: S1939-4551(23)00069-8
pmc: PMC10458346
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100809Informations de copyright
© 2023 Published by Elsevier Inc. on behalf of World Allergy Organization.
Déclaration de conflit d'intérêts
None.
Références
Eur J Emerg Med. 2017 Oct;24(5):318-325
pubmed: 28059860
Front Genet. 2022 Jul 18;13:914376
pubmed: 35923707
N Engl J Med. 2015 Jan 29;372(5):418-25
pubmed: 25629740
Chest. 2006 Jan;129(1 Suppl):169S-173S
pubmed: 16428706
J Community Hosp Intern Med Perspect. 2019 Dec 14;9(6):453-459
pubmed: 32002148
Medicine (Baltimore). 2015 Nov;94(45):e1939
pubmed: 26559262
N Engl J Med. 2010 Aug 5;363(6):532-41
pubmed: 20818888
Hypertension. 2009 Sep;54(3):516-23
pubmed: 19581505
J Allergy Clin Immunol Pract. 2017 Sep - Oct;5(5):1402-1409.e3
pubmed: 28552382
Intern Med J. 2015 Aug;45(8):821-7
pubmed: 25944565
Hypertension. 2008 Jun;51(6):1624-30
pubmed: 18413488
JAMA. 1997 Jul 16;278(3):232-3
pubmed: 9218671
Hypertension. 2001 Jan;37(1):46-51
pubmed: 11208755
Am J Cardiovasc Drugs. 2012 Aug 1;12(4):263-77
pubmed: 22587776
J Allergy Clin Immunol Pract. 2017 May - Jun;5(3):744-749
pubmed: 28377081
J Vet Intern Med. 2019 Mar;33(2):363-382
pubmed: 30806496
Allergy. 2014 May;69(5):602-16
pubmed: 24673465
PLoS One. 2019 Nov 11;14(11):e0224858
pubmed: 31710633
Clin Mol Allergy. 2021 Dec 6;19(1):24
pubmed: 34872575
Ann Intern Med. 2017 Jul 18;167(2):142-143
pubmed: 28554195
Hypertension. 2008 Jan;51(1):141-7
pubmed: 18025295
Arch Intern Med. 2004 Apr 26;164(8):910-3
pubmed: 15111379
CMAJ. 2006 Oct 24;175(9):1065-70
pubmed: 17060655
Rev Med Interne. 2013 Apr;34(4):209-13
pubmed: 23380506
N Engl J Med. 2008 Apr 10;358(15):1547-59
pubmed: 18378520
J Community Hosp Intern Med Perspect. 2020 Feb 10;10(1):16-18
pubmed: 32128053
Clin Exp Allergy. 2010 Jan;40(1):50-61
pubmed: 19659669
J Card Fail. 2022 May;28(5):e1-e167
pubmed: 35378257
Am J Cardiol. 2012 Aug 1;110(3):383-91
pubmed: 22521308
Allergy. 2014 Jul;69(7):868-87
pubmed: 24785199
J Allergy Clin Immunol. 2004 Sep;114(3 Suppl):S51-131
pubmed: 15356535
J Allergy Clin Immunol. 2017 Jul;140(1):242-248.e2
pubmed: 27913306
Am J Hypertens. 2004 Feb;17(2):103-11
pubmed: 14751650
Ann Allergy Asthma Immunol. 2008 Nov;101(5):495-9
pubmed: 19055203
Ann Emerg Med. 2010 Sep;56(3):278-82
pubmed: 20447725
Curr Vasc Pharmacol. 2014 Mar;12(2):223-48
pubmed: 24568157
J Intern Med. 2019 May;285(5):553-561
pubmed: 30618189
Orphanet J Rare Dis. 2018 May 4;13(1):73
pubmed: 29728119